Alterity Therapeutics Limited Share Price
Stocks
ATH
AU0000043945
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Australian S.E.
06:10:31 09/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.3550 AUD | -2.74% |
|
-6.58% | -11.25% |
| 09-16 | Lake Street Initiates Alterity Therapeutics at Buy With $10 Price Target | MT |
| 08-31 | Alterity Therapeutics Enters Underwriting Agreement for Exercise of up to 8.4 Million Listed Options | MT |
| Market Cap | 58.16M 51.93M 48.45M 44.01M 82.82M 5.63B 83.62M 582M 228M 2.86B 218M 214M 9.2B | P/E 2027 * |
-3.56x | P/E 2028 * | -0.33x |
|---|---|---|---|---|---|
| Enterprise Value | 48.2M 43.04M 40.16M 36.48M 68.64M 4.67B 69.31M 482M 189M 2.37B 181M 177M 7.63B | EV / Sales 2027 * |
44.5x | EV / Sales 2028 * | 10.9x |
| Free-Float |
97.02% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| ATH | Delayed | |
OTC Markets
| PRNAF | Delayed | |
|
Deutsche Boerse AG
| PBN | Delayed | |
|
Börse Stuttgart
| PBN | Delayed |
Last Transcript: Alterity Therapeutics Limited
| 1 day | -2.74% | ||
| 1 week | -6.58% | ||
| Current month | -11.80% | ||
| 1 month | -29.70% | ||
| 3 months | -44.96% | ||
| 6 months | -21.11% | ||
| Current year | -11.25% |
| 1 week | 0.35 |  | 0.41 |
| 1 month | 0.35 | | 0.5 |
| Current year | 0.35 | | 0.78 |
| 1 year | 0.35 | | 0.78 |
| 3 years | 0.1 | | 0.95 |
| 5 years | 0.1 | | 1.65 |
| 10 years | 0.1 | | 20.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 06/01/2021 |
| Director of Finance/CFO | - | 29/09/2024 | |
| Chief Tech/Sci/R&D Officer | - | 31/03/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 28/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 07/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 20/11/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/08/26 | Exercice | Director | 47,620 | 0.0216% | ||
| 31/08/26 | Buy | Chief Executive Officer | -47,620 | 0.0216% | ||
| 31/08/26 | Buy | Director | 95,240 | 0.0432% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.74% | -6.58% | -29.00% | +1.43% | 58.16M | |
| -3.19% | -3.19% | +44.60% | +87.98% | 72.13B | |
| +3.91% | -10.01% | +5.64% | +57.13% | 49.41B | |
| +1.33% | +0.81% | +4.78% | +32.91% | 47.24B | |
| -6.35% | -8.63% | +293.39% | +651.28% | 40.32B | |
| +0.30% | -0.71% | +29.05% | +30.33% | 42.61B | |
| -3.82% | -2.41% | -0.27% | +101.36% | 39.81B | |
| -2.13% | -2.18% | +7.51% | +50.31% | 30.52B | |
| -3.35% | -4.95% | -13.38% | -17.22% | 23.13B | |
| +2.78% | +7.22% | +17.19% | -0.70% | 21.09B | |
| Average | -0.63% | -4.39% | +35.95% | +99.48% | 36.63B | |
| Weighted average by Cap. | -0.66% | -3.85% | +46.57% | +118.57% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 1.08M 968K 903K 820K 1.54M 105M 1.56M 10.84M 4.24M 53.33M 4.07M 3.98M 172M | 1.95M 1.74M 1.63M 1.48M 2.78M 189M 2.81M 19.54M 7.64M 96.15M 7.34M 7.18M 309M |
| Net income | -27.31M -24.39M -22.75M -20.67M -38.89M -2.65B -39.27M -273M -107M -1.34B -103M -100M -4.32B | -30.69M -27.41M -25.57M -23.23M -43.71M -2.97B -44.13M -307M -120M -1.51B -115M -113M -4.86B |
| Net Debt | -9.95M -8.89M -8.29M -7.53M -14.17M -964M -14.31M -99.55M -38.94M -490M -37.37M -36.56M -1.58B | -36.93M -32.98M -30.77M -27.95M -52.59M -3.58B -53.11M -369M -144M -1.82B -139M -136M -5.85B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/10/26 | A$0.3550 | -2.74% | 334,282 |
| 08/10/26 | A$0.3650 | -3.95% | 188,623 |
| 07/10/26 | A$0.3800 | -5.00% | 560,606 |
| 06/10/26 | A$0.4000 | +8.11% | 340,800 |
| 05/10/26 | A$0.3700 | -2.63% | 497,602 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ATH Stock
Select your edition
All financial news and data tailored to specific country editions
